Analytical Data
-
Gene name
IL36RN
- Application
-
Alternative Names
IL36RN;FIL1D;IL1F5;IL1HY1;Interleukin-36 receptor antagonist Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UBH0
-
Expression Region
2-155aa
-
AA Sequence
VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAEKVIKGEE ISVVPN RALD ASLSPVILGV QGGSQCLSCG TEKGPILKLE PVNIMELYLG A KESKSFTFY RRDMGLTSSF ESAAYPGWFL CTSPEADQPV RLTQIPE DPA WDAPITDFYF QQCD
-
Molecular Weight
17 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL36RN (Interleukin-36 Receptor Antagonist) is a critical component in the regulation of the immune system and has garnered increasing attention in recent years due to its role in various inflammatory diseases, particularly in skin disorders like psoriasis and other autoinflammatory conditions. IL36RN encodes a protein that acts as a natural antagonist to the interleukin-36 (IL-36) cytokines, which are important mediators of the inflammatory response. Mutations or deficiencies in IL36RN have been linked to severe forms of generalized pustular psoriasis (GPP), highlighting its significance in maintaining immune homeostasis. Research on recombinant IL36RN protein has focused on its therapeutic potential in modulating excessive inflammatory responses by blocking the action of IL-36 cytokines. This has led to the exploration of IL36RN as a candidate for targeted therapies in treating both chronic inflammatory diseases and acute flare-ups. Furthermore, understanding the structure and function of the IL36RN protein enables researchers to investigate its interactions with other components of the immune system, providing insights into the underlying mechanisms of inflammation and paving the way for innovative treatment strategies that could improve patient outcomes in autoinflammatory diseases. Thus, IL36RN recombinant protein research is critical not only for elucidating its biological functions but also for developing new therapeutic avenues for managing inflammation-driven diseases.
